The increasing characterization of childhood acute lymphoblastic leukemia (ALL) has led to the identification of multiple molecular targets, but have yet to translate into more effective targeted therapies, particularly for high-risk, relapsed T-cell ALL. Searching for master regulators controlling multiple signaling pathways in T-ALL, we investigated the multi-functional protein 
INTRODUCTION
Clinical studies using selective inhibitors of signaling molecules support the notion that, in most cancers, effective, curative therapeutic strategies require the concurrent disruption of multiple molecular targets or pathways (1, 2) . Accordingly, the focus of targeted therapies is shifting to the identification of combinations of signaling inhibitors that optimally promote tumor cytotoxicity and overcome drug resistance on defined cancers, while preventing the emergence of tumor variants that may lead to cancer recurrence. In this context, the clinical development of drugs that disrupt master molecular regulators controlling the activity of multiple non-recurrent signaling pathways or transcription programs has great potential.
Ref-1 (redox factor-1; AP endonuclease 1, APE1; APEX1) is a multifunctional protein acting as a unique nuclear reduction-oxidation (redox) factor and a DNA repair endonuclease (3) . In contrast to general reduction-oxidation systems, Ref-1 directly reduces cysteine residues in the DNA binding and activation domains of target transcription factors (TFs) (4), thus controlling their binding to target promoter sequences and their downstream transcriptional programs (3, therapeutic challenges (13) (14) (15) (16) . In adult T-ALL, current therapies are much less effective, with high relapse rates and poor outcomes. Marked progress in the molecular characterization of Tcell ALL raised the prospect of a new generation of more efficient, selective therapies, particularly for high-risk and relapsed patients. This included the targeting of Notch signaling, which seems to function as an oncogenic driver in the majority of T-ALL (17) (18) (19) . However, clinical trials with Notch pathway inhibitors showed limited efficacy and were hampered by significant toxicities, and studies showed that presence of Notch mutations is not associated with poor prognosis and that those patients may be in fact more responsive to conventional therapies (20) . Other signaling effectors or pathways were identified as potential therapeutic targets for pediatric T-ALL, including PI3K/Akt, mTOR/TORC1, NF-κB, Gfi-1, CXCL12/CXCR4 and others (21) (22) (23) (24) (25) . Inhibitory compounds targeting these pathways are in preclinical development or in clinical studies, but the use of signaling antagonists has yet to lead to transformative clinical successes in ALL patients. Therefore, the need remains for more effective, less toxic targeted therapies for high-risk, refractory and relapsed T-cell ALL.
In search for master molecular regulators of transcriptional programs in T-cell ALL, we 
MATERIALS AND METHODS

Leukemia T-cells and Specimens.
No clinical studies were performed in this work. Leukemia specimens were collected according with the protocol approved by the Indiana University Institutional Review Board. All leukemia specimens were unidentified, and no patient information was collected or used in this study. TAIL7, a human IL-7-dependent leukemia T-cell line that mimics the functional and molecular properties of primary T-ALL cells, was established in our laboratory in 2004 (27) . Primary T-ALL cells were obtained from diagnostic specimens of pediatric patients with high leukemia involvement (>90%) in 2015. After gradient centrifugation, cells were washed in RPMI-10.
Animal model of Notch-induced T-ALL and xenograft model of human T-ALL.
Animal models of leukemia (Notch-induced T-ALL; xenograft model of human T-ALL) were performed using protocols approved by the Indiana University School of Medicine IACUC. For the Notch-induced leukemia model, hematopoietic progenitor Lin-cells were purified from donor C57BL/6 mice (CD45.2+), and transduced with MSCV-ICN/GFP (ICN) viral particles (28) . Equal numbers of transduced Lin-GFP+ICN+ cells (20,000/mice) were injected I.V. into lethally irradiated 8-wk old recipient BoyJ (CD45.1+) admixed with a radio-protective dose of BM cells (CD45.1+). This model has 100% penetrance, with leukemia progression correlating with increased WBC counts, circulating blasts and splenomegaly. Mice were bled weekly for WBC counts and quantification of leukemia cells, and were sacrificed at stage of terminal disease, at which they exhibit high content of blasts in PB, BM and spleen, with most leukemia cells being GFP+ CD4+ CD8+ (DP) T-cells. Cells were isolated from harvested femur bones and spleens, and processed for biochemical and functional studies.
For the xenograft human T-ALL model, TAIL7 cells (1x10 6 ) were transplanted i.v. into NOD/SCID or NSG mice (7-9wk old) (27, 29) . Mice were bled weekly for presence of human blasts in the PB, by flow cytometry. Animals exhibiting >2% circulating human leukemia blasts were randomly allocated into experimental groups, and initiated treatment with Vincristine (i.p., 0.5mg/Kg, every 4 days for 3 weeks) or control vehicle. Mice were sacrificed at stage of terminal disease (very high leukemia cell content in BM), and leukemia cells were isolated from harvested femurs, and processed for functional studies. 
Immunoblotting.
Cell lysates were prepared in RIPA lysis buffer system (Santa Cruz Biotechnology, Dallas, TX), as described (21, 22) . All experiments with TAIL7 cells were performed using IL-7 (10ng/ml). 
Immunohistochemistry.
Formalin-fixed, paraffin-embedded tissue samples from pediatric patients with T-ALL at the time of original diagnosis were used for immunohistochemistry. 
Electrophoretic Mobility Shift Assay (EMSA).
Redox-EMSA were performed as previously described (34), with some modifications.
Briefly, nuclear extracts were prepared from leukemia TAIL7 cells cultured in IL-7, as described (21, 22, 27) . 
Gene Expression by Quantitative PCR.
Quantitative PCR (qPCR) was used to quantify levels of defined mRNA transcripts in leukemia cells. RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen; Valencia, CA), according to manufacturer's instructions. cDNA was prepared using reserve transcriptase (Applied Biosystems, ABI; Foster City, CA), as described. (35) qPCR was performed using
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Taqman Gene Expression Assays for Ref-1, Survivin/BIRC5, and Bcl-xL expression (ABI), or
SYBR® Green-based assay using the Brilliant II SYBR Green Kit (Agilent Technologies; Santa Clara, CA) for the other transcripts analyzed, in a 7900HT Fast Real-Time PCR System (ABI).
Quantification was performed using the comparative C t method, with GAPDH or 18S rRNA being used as reference, endogenous controls. In each experiment, assays were performed in duplicate or triplicate for each sample.
Viability Studies with E3330.
Leukemia cell viability was determined using the CellTiter-Glo® ATP assay (Promega;
Madison, WI), according to the manufacturer's instructions. For experiments with E3330, leukemia cells were cultured with RPMI supplemented with 5% FBS (RPMI-5). TAIL7 cells were cultured with IL-7 (10ng/ml), and TALL-104 cells with IL-2 (20ng/mL; R&D Systems).
Primary T-ALL cells were cultured with IL-7 plus IL-9 (10ng/ml; R&D Systems), and leukemia cells from the ICN-induced T-ALL model were cultured with IL-7 (10ng/mL), SCF (10ng/mL; R&D Systems) and FLT3L (10ng/mL; R&D Systems). All cultures were performed in triplicates, for the timepoints indicated. Plates were analyzed in a SpectraMax Gemini EM microplate reader (Molecular Devices; Sunnyvale, CA).
Apoptosis Assay.
For apoptosis studies, leukemia cells were cultured with 25 or 40μM E3330, in RPMI-5. At the timepoints indicated, cells were resuspended in binding buffer, stained with FITCconjugated Annexin V (1μl/ml; BD-Biosciences) and Propidium Iodide (PI; 5μg/ml, 15min), and analyzed by flow cytometry.
Statistics.
Differences between experimental study conditions were evaluated using the statistical tests indicated in the respective Figure Legends . Differences of means were considered statistically significant for p<0.05.
RESULTS
The Ref-1 multi-function protein is expressed in leukemia T-cells
A data mining search for regulators that may control critical leukemia-associated 
without affecting its DNA repair function (7) . As shown in Figure 2B , incubation of reduced Ref- 
Selective blockade of Ref-1 redox potently inhibit leukemia T-cells, including drugresistant, relapsed T-ALL cells
Functional studies were performed to determine the impact of Ref-1 blockade in leukemia T-cells, by using E3330, a highly selective compound that recognizes a redox-active Ref-1 protein (11, 12, 43) . First, we evaluated the effect of E3330 on leukemia cell viability, using the T-ALL cell lines described above (Supplementary Table 1 We next evaluated the activity of Ref-1 redox blockade by E3330 in primary cells from leukemia patients, using the ATP assay. As seen in Figure 5A , E3330 markedly inhibited leukemia T-cell viability in all cases tested, including a specimen from a T-ALL relapse patient (Pt_B). We then investigated the efficacy of E3330 in leukemia cells obtained from mice exhibiting terminal ICN-induced T-cell leukemia, as described above (38, 39) . Cells were isolated from the BM and spleen of mice with terminal leukemia, which is characterized by massive splenomegaly, hepatomegaly, and high leukemia cell content in these organs. As shown in Figure 5B and these systems have been implicated in leukemogenesis. In ALL, it has been reported that the levels of GSH, Trx and peroxiredoxin are increased, whereas SOD is reduced (26, (51) (52) (53) .
In particular, thioredoxin is increased in T-ALL specimens, namely in cases with high WBC counts, and it has been suggested that selective inhibition of Trx may represent an effective strategy to overcome drug resistance and to sensitize leukemia T-cells to conventional chemotherapy drugs (26) . Interestingly, it has been shown that Trx can reduce and thereby E3330 is a small molecule that was initially described as an inhibitor of NF-κB activation binding-defective cold probe (25-, 50-or 75-fold). B) NF-κB redox-EMSA in extracts from TAIL7 cells treated with increasing doses of E3330. DTT final dose was 0.02mM. C).
Densitometry quantification of effect of E3330 on NF-κB DNA binding in TAIL7 cells; data shown as mean ± SEM from two independent experiments. *p<0.05, **p<0.01, using T-test. 
